Predictors of advanced chronic kidney disease and end-stage renal disease in HIV-positive persons.
Identifieur interne : 003A04 ( PubMed/Corpus ); précédent : 003A03; suivant : 003A05Predictors of advanced chronic kidney disease and end-stage renal disease in HIV-positive persons.
Auteurs : Lene Ryom ; Amanda Mocroft ; Ole Kirk ; Michael Ross ; Peter Reiss ; Christophe A. Fux ; Philippe Morlat ; Olivier Moranne ; Colette Smith ; Wafaa El-Sadr ; Matthew Law ; Jens D. LundgrenSource :
- AIDS (London, England) [ 1473-5571 ] ; 2014.
English descriptors
- KwdEn :
- Adult, Anti-Retroviral Agents (adverse effects), Anti-Retroviral Agents (therapeutic use), Cohort Studies, Female, Follow-Up Studies, HIV Infections (complications), Humans, Kidney Failure, Chronic (chemically induced), Kidney Failure, Chronic (epidemiology), Male, Prospective Studies, Renal Insufficiency, Chronic (chemically induced), Renal Insufficiency, Chronic (epidemiology), Risk Factors.
- MESH :
- chemical , adverse effects : Anti-Retroviral Agents.
- chemical , therapeutic use : Anti-Retroviral Agents.
- chemically induced : Kidney Failure, Chronic, Renal Insufficiency, Chronic.
- complications : HIV Infections.
- epidemiology : Kidney Failure, Chronic, Renal Insufficiency, Chronic.
- Adult, Cohort Studies, Female, Follow-Up Studies, Humans, Male, Prospective Studies, Risk Factors.
Abstract
Whilst several antiretroviral drugs have been associated with moderate chronic kidney disease (CKD), their contribution to advanced CKD and end-stage renal disease (ESRD) remain unknown.
DOI: 10.1097/QAD.0000000000000042
PubMed: 24361680
Links to Exploration step
pubmed:24361680Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Predictors of advanced chronic kidney disease and end-stage renal disease in HIV-positive persons.</title><author><name sortKey="Ryom, Lene" sort="Ryom, Lene" uniqKey="Ryom L" first="Lene" last="Ryom">Lene Ryom</name><affiliation><nlm:affiliation>aCopenhagen HIV Programme, University of Copenhagen, Faculty of Health and Medical Sciences and Epidemiklinikken M5132, Copenhagen University Hospital/Rigshospitalet, Copenhagen, Denmark bResearch Department of Infection and Population Health, UCL, London, UK cDivision of Nephrology, Mount Sinai School of Medicine, New York, USA dAcademic Medical Center, University of Amsterdam, and Stichting HIV Monitoring, The Netherlands eClinic for Infectious Diseases and Hospital Hygiene, Kantonsspital Aarau, Switzerland fService de médecine interne et maladies infectieuses, Hôpital Saint-André, CHU de Bordeaux gNephrology Department, Public Health Department, CHU Nice, France hICAP-Columbia University and Harlem Hospital, New York, USA iKirby Institute, Sydney, Australia.</nlm:affiliation></affiliation></author><author><name sortKey="Mocroft, Amanda" sort="Mocroft, Amanda" uniqKey="Mocroft A" first="Amanda" last="Mocroft">Amanda Mocroft</name></author><author><name sortKey="Kirk, Ole" sort="Kirk, Ole" uniqKey="Kirk O" first="Ole" last="Kirk">Ole Kirk</name></author><author><name sortKey="Ross, Michael" sort="Ross, Michael" uniqKey="Ross M" first="Michael" last="Ross">Michael Ross</name></author><author><name sortKey="Reiss, Peter" sort="Reiss, Peter" uniqKey="Reiss P" first="Peter" last="Reiss">Peter Reiss</name></author><author><name sortKey="Fux, Christophe A" sort="Fux, Christophe A" uniqKey="Fux C" first="Christophe A" last="Fux">Christophe A. Fux</name></author><author><name sortKey="Morlat, Philippe" sort="Morlat, Philippe" uniqKey="Morlat P" first="Philippe" last="Morlat">Philippe Morlat</name></author><author><name sortKey="Moranne, Olivier" sort="Moranne, Olivier" uniqKey="Moranne O" first="Olivier" last="Moranne">Olivier Moranne</name></author><author><name sortKey="Smith, Colette" sort="Smith, Colette" uniqKey="Smith C" first="Colette" last="Smith">Colette Smith</name></author><author><name sortKey="El Sadr, Wafaa" sort="El Sadr, Wafaa" uniqKey="El Sadr W" first="Wafaa" last="El-Sadr">Wafaa El-Sadr</name></author><author><name sortKey="Law, Matthew" sort="Law, Matthew" uniqKey="Law M" first="Matthew" last="Law">Matthew Law</name></author><author><name sortKey="Lundgren, Jens D" sort="Lundgren, Jens D" uniqKey="Lundgren J" first="Jens D" last="Lundgren">Jens D. Lundgren</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2014">2014</date><idno type="RBID">pubmed:24361680</idno><idno type="pmid">24361680</idno><idno type="doi">10.1097/QAD.0000000000000042</idno><idno type="wicri:Area/PubMed/Corpus">003A04</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">003A04</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Predictors of advanced chronic kidney disease and end-stage renal disease in HIV-positive persons.</title><author><name sortKey="Ryom, Lene" sort="Ryom, Lene" uniqKey="Ryom L" first="Lene" last="Ryom">Lene Ryom</name><affiliation><nlm:affiliation>aCopenhagen HIV Programme, University of Copenhagen, Faculty of Health and Medical Sciences and Epidemiklinikken M5132, Copenhagen University Hospital/Rigshospitalet, Copenhagen, Denmark bResearch Department of Infection and Population Health, UCL, London, UK cDivision of Nephrology, Mount Sinai School of Medicine, New York, USA dAcademic Medical Center, University of Amsterdam, and Stichting HIV Monitoring, The Netherlands eClinic for Infectious Diseases and Hospital Hygiene, Kantonsspital Aarau, Switzerland fService de médecine interne et maladies infectieuses, Hôpital Saint-André, CHU de Bordeaux gNephrology Department, Public Health Department, CHU Nice, France hICAP-Columbia University and Harlem Hospital, New York, USA iKirby Institute, Sydney, Australia.</nlm:affiliation></affiliation></author><author><name sortKey="Mocroft, Amanda" sort="Mocroft, Amanda" uniqKey="Mocroft A" first="Amanda" last="Mocroft">Amanda Mocroft</name></author><author><name sortKey="Kirk, Ole" sort="Kirk, Ole" uniqKey="Kirk O" first="Ole" last="Kirk">Ole Kirk</name></author><author><name sortKey="Ross, Michael" sort="Ross, Michael" uniqKey="Ross M" first="Michael" last="Ross">Michael Ross</name></author><author><name sortKey="Reiss, Peter" sort="Reiss, Peter" uniqKey="Reiss P" first="Peter" last="Reiss">Peter Reiss</name></author><author><name sortKey="Fux, Christophe A" sort="Fux, Christophe A" uniqKey="Fux C" first="Christophe A" last="Fux">Christophe A. Fux</name></author><author><name sortKey="Morlat, Philippe" sort="Morlat, Philippe" uniqKey="Morlat P" first="Philippe" last="Morlat">Philippe Morlat</name></author><author><name sortKey="Moranne, Olivier" sort="Moranne, Olivier" uniqKey="Moranne O" first="Olivier" last="Moranne">Olivier Moranne</name></author><author><name sortKey="Smith, Colette" sort="Smith, Colette" uniqKey="Smith C" first="Colette" last="Smith">Colette Smith</name></author><author><name sortKey="El Sadr, Wafaa" sort="El Sadr, Wafaa" uniqKey="El Sadr W" first="Wafaa" last="El-Sadr">Wafaa El-Sadr</name></author><author><name sortKey="Law, Matthew" sort="Law, Matthew" uniqKey="Law M" first="Matthew" last="Law">Matthew Law</name></author><author><name sortKey="Lundgren, Jens D" sort="Lundgren, Jens D" uniqKey="Lundgren J" first="Jens D" last="Lundgren">Jens D. Lundgren</name></author></analytic><series><title level="j">AIDS (London, England)</title><idno type="eISSN">1473-5571</idno><imprint><date when="2014" type="published">2014</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult</term><term>Anti-Retroviral Agents (adverse effects)</term><term>Anti-Retroviral Agents (therapeutic use)</term><term>Cohort Studies</term><term>Female</term><term>Follow-Up Studies</term><term>HIV Infections (complications)</term><term>Humans</term><term>Kidney Failure, Chronic (chemically induced)</term><term>Kidney Failure, Chronic (epidemiology)</term><term>Male</term><term>Prospective Studies</term><term>Renal Insufficiency, Chronic (chemically induced)</term><term>Renal Insufficiency, Chronic (epidemiology)</term><term>Risk Factors</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Anti-Retroviral Agents</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Anti-Retroviral Agents</term></keywords><keywords scheme="MESH" qualifier="chemically induced" xml:lang="en"><term>Kidney Failure, Chronic</term><term>Renal Insufficiency, Chronic</term></keywords><keywords scheme="MESH" qualifier="complications" xml:lang="en"><term>HIV Infections</term></keywords><keywords scheme="MESH" qualifier="epidemiology" xml:lang="en"><term>Kidney Failure, Chronic</term><term>Renal Insufficiency, Chronic</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adult</term><term>Cohort Studies</term><term>Female</term><term>Follow-Up Studies</term><term>Humans</term><term>Male</term><term>Prospective Studies</term><term>Risk Factors</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Whilst several antiretroviral drugs have been associated with moderate chronic kidney disease (CKD), their contribution to advanced CKD and end-stage renal disease (ESRD) remain unknown.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">24361680</PMID><DateCreated><Year>2014</Year><Month>01</Month><Day>13</Day></DateCreated><DateCompleted><Year>2014</Year><Month>09</Month><Day>04</Day></DateCompleted><DateRevised><Year>2014</Year><Month>01</Month><Day>13</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1473-5571</ISSN><JournalIssue CitedMedium="Internet"><Volume>28</Volume><Issue>2</Issue><PubDate><Year>2014</Year><Month>Jan</Month><Day>14</Day></PubDate></JournalIssue><Title>AIDS (London, England)</Title><ISOAbbreviation>AIDS</ISOAbbreviation></Journal><ArticleTitle>Predictors of advanced chronic kidney disease and end-stage renal disease in HIV-positive persons.</ArticleTitle><Pagination><MedlinePgn>187-99</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1097/QAD.0000000000000042</ELocationID><Abstract><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">Whilst several antiretroviral drugs have been associated with moderate chronic kidney disease (CKD), their contribution to advanced CKD and end-stage renal disease (ESRD) remain unknown.</AbstractText><AbstractText Label="DESIGN" NlmCategory="METHODS">D:A:D participants with at least three estimated glomerular filtration rates (eGFR) after February 2004 were followed until the first of advanced CKD (confirmed eGFR ≤ 30 ml/min, ≥3 months apart), ESRD (dialysis ≥3 months/ transplantation), 6 months after last visit or February 2012.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Poisson regression was used to assess risk factors for advanced CKD/ESRD including exposure to potential nephrotoxic antiretroviral drugs and antiretroviral drug discontinuation rates according to latest eGFR.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Among 35 192 persons contributing 200 119 person years of follow-up (PYFU), 135 (0.4%) developed advanced CKD (n = 114)/ESRD (n = 21); incidence rate = 0.67 [95% confidence interval (CI), 0.56-0.79]/1000 PYFU. Tenofovir (TDF) was particularly frequently discontinued as eGFR declined. After adjustment, those previously exposed but currently off TDF had similar advanced CKD/ESRD rate ratios compared with those unexposed [1.00 (95% CI, 0.66-1.51)], while those currently on TDF had reduced rates [0.23 (95% CI, 0.13-0.41)]. No consistent associations with other antiretroviral drugs were seen. Results were robust after time-lagging antiretroviral drug exposure, stratifying by baseline eGFR, and allowing for competing risks. Other predictors were diabetes, hypertension, baseline eGFR, smoking and current CD4 cell count. The incidence rate in nonsmokers with baseline eGFR > 60 and no diabetes or hypertension was 0.16 (95% CI 0.09-0.26)/1000 PYFU.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Neither current nor recent antiretroviral drug use predicted advanced CKD/ESRD during 6 years median follow-up in a large, heterogenenous and primarily white cohort. TDF discontinuation rates increased with decreasing eGFR, leaving a selected group still on TDF at lower advanced CKD/ESRD risk. Traditional renal risk factors and current CD4 cell count were the strongest advanced CKD/ESRD predictors.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ryom</LastName><ForeName>Lene</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>aCopenhagen HIV Programme, University of Copenhagen, Faculty of Health and Medical Sciences and Epidemiklinikken M5132, Copenhagen University Hospital/Rigshospitalet, Copenhagen, Denmark bResearch Department of Infection and Population Health, UCL, London, UK cDivision of Nephrology, Mount Sinai School of Medicine, New York, USA dAcademic Medical Center, University of Amsterdam, and Stichting HIV Monitoring, The Netherlands eClinic for Infectious Diseases and Hospital Hygiene, Kantonsspital Aarau, Switzerland fService de médecine interne et maladies infectieuses, Hôpital Saint-André, CHU de Bordeaux gNephrology Department, Public Health Department, CHU Nice, France hICAP-Columbia University and Harlem Hospital, New York, USA iKirby Institute, Sydney, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mocroft</LastName><ForeName>Amanda</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Kirk</LastName><ForeName>Ole</ForeName><Initials>O</Initials></Author><Author ValidYN="Y"><LastName>Ross</LastName><ForeName>Michael</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Reiss</LastName><ForeName>Peter</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Fux</LastName><ForeName>Christophe A</ForeName><Initials>CA</Initials></Author><Author ValidYN="Y"><LastName>Morlat</LastName><ForeName>Philippe</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Moranne</LastName><ForeName>Olivier</ForeName><Initials>O</Initials></Author><Author ValidYN="Y"><LastName>Smith</LastName><ForeName>Colette</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>El-Sadr</LastName><ForeName>Wafaa</ForeName><Initials>W</Initials></Author><Author ValidYN="Y"><LastName>Law</LastName><ForeName>Matthew</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Lundgren</LastName><ForeName>Jens D</ForeName><Initials>JD</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>5U01AI042170-10</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>5U01AI046362-03</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01-AI069907</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>AIDS</MedlineTA><NlmUniqueID>8710219</NlmUniqueID><ISSNLinking>0269-9370</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D044966">Anti-Retroviral Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CitationSubset>X</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D044966" MajorTopicYN="N">Anti-Retroviral Agents</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005500" MajorTopicYN="N">Follow-Up Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015658" MajorTopicYN="N">HIV Infections</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007676" MajorTopicYN="N">Kidney Failure, Chronic</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="Y">chemically induced</QualifierName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051436" MajorTopicYN="N">Renal Insufficiency, Chronic</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="Y">chemically induced</QualifierName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2013</Year><Month>12</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2013</Year><Month>12</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2014</Year><Month>9</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">24361680</ArticleId><ArticleId IdType="doi">10.1097/QAD.0000000000000042</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/PubMed/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 003A04 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 003A04 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Asie
|area= AustralieFrV1
|flux= PubMed
|étape= Corpus
|type= RBID
|clé= pubmed:24361680
|texte= Predictors of advanced chronic kidney disease and end-stage renal disease in HIV-positive persons.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i -Sk "pubmed:24361680" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a AustralieFrV1
| This area was generated with Dilib version V0.6.33. |  |